Ekso Bionics
American business enterprise
Ekso Bionics Holdings Inc. is a company that develops and manufactures powered exoskeleton bionic devices that can be strapped on as wearable robots to enhance the strength, mobility, and endurance of industrial workers and people experiencing paralysis and mobility issues after a brain injury, stroke, multiple sclerosis (MS) or spinal cord injury. They enable individuals with any amount of lower extremity weakness, including those who are paralyzed, to stand up and walk.
Ekso Bionics currently focuses in the health and industrial sectors.
The company's first commercially available health product was called EksoGT (formerly eLEGS). Ekso Bionics is the original developer of HULC, now under military development by Lockheed Martin, and the current developers of EksoNR, which allows patients who are relearning to walk the ability to stand and take steps. In December 2022, Ekso Bionics acquired the Human Motion & Control business unit from Parker Hannifin which includes the Indego product line. This acquisition allowed Ekso Bionics to begin selling exoskeletons to those who have an SCI and want a personal exoskeleton to walk at home and in their community. This personal exoskeleton is available to eligible Medicare beneficiaries for reimbursement starting in April 2024.
Ekso was selected as Wired magazine's number two "Most Significant Gadget of 2010", and was included in Time magazine's "50 Best Innovations of 2010".
“Ekso Bionics” enters the record as american business enterprise. Crown Archives preserves that source wording while asking what Ekso, Bionics and American can confirm, complicate or overturn.
Why this record matters
“Ekso Bionics” is worth following because a concise public description often conceals a longer documentary argument. Here, Ekso, Bionics and American provides the most credible route into that argument.
Named sources, stable identifiers and responsible institutions provide the strongest route from overview to verifiable evidence. The source revision retrieved here is dated Jul 29, 2026. The linked authority identifier is Q5350582. 2 of 2 selected statements include explicit references; 0 carry qualifiers and 0 use preferred rank. The first chronological checks are 2022, 2024 and 2010.
A concise general-reference account can conceal disagreements about scope, terminology or the weight assigned to individual sources. The source lead contains qualifying language; that uncertainty should survive quotation, summary and reuse. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Use the entry as an orientation point, then follow its citations and revision history. Names, dates and institutional relationships should be checked against the original record.
- Subject orientation
- Search vocabulary
- Locating named sources
The closest primary source, responsible institution and strongest cited specialist reference.
Three-step research path
- Establish the record: confirm the title “Ekso Bionics”, its source revision and the description used here.
- Expand the search: follow Ekso Bionics primary sources, Ekso Bionics archive and Ekso research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “Ekso Bionics”?
- Which cited source is closest to the event, object or claim?
- Which institution is responsible for the underlying evidence?
Search terms from this dossier
This entry incorporates text from “Ekso Bionics” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.